RxDoctor Payments Data

Angela Kueck, MD

Gynecologic Oncology · Ypsilanti, MINPI 1427016989

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 22 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 10 manufacturers reported payments, led by Immunogen, Inc. at 36.2% of the total. Reporting peaked in 2023 at $415 and has fallen 92.4% since, to $31 in 2024. That places this record below the midpoint for gynecologic oncology clinicians in MI, where the typical reported total is $894.

$761in general payments, 2019–2025

Across 22 payments — averaging $34.57 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Immunogen, Inc.$275
  • Clovis Oncology, Inc.$132
  • Seagen Inc.$80
  • Myriad Genetic Laboratories, Inc.$78
  • Johnson & Johnson$70
  • Eisai Inc.$41
  • plus $85 from 4 others

What the payments were for

  • Food & beverage$761100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$761 in reported general payments places this provider in the 40th percentile of 43 gynecologic oncology providers in Michigan.

See all gynecologic oncology providers in Michigan

Medicare billing

Part B allowed, 2024
$66,068
Medicare patients
86
Services billed
340

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
LynparzaOlaparib12$143,396
Prochlorperazine Maleate38$843
Dexamethasone29$466
Olanzapine25$164

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaLynparza$25$143,39612 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 40th percentile of 43 gynecologic oncology providers in Michigan.

Other gynecologic oncology in Ypsilanti

See the full list for Michigan

Where these figures come from

Is this you, or does something look wrong? →